Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Change in Inventory (2016 - 2025)

IGC Pharma (IGC) has disclosed Change in Inventory for 16 consecutive years, with -$6000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Inventory changed N/A to -$6000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$167000.0, a 83.68% increase, with the full-year FY2025 number at -$180000.0, up 82.14% from a year prior.
  • Change in Inventory was -$6000.0 for Q3 2025 at IGC Pharma, up from -$11000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $322000.0 in Q1 2021 to a low of -$1.9 million in Q1 2022.
  • A 5-year average of -$206111.1 and a median of -$8000.0 in 2023 define the central range for Change in Inventory.
  • Biggest YoY gain for Change in Inventory was 3800.0% in 2022; the steepest drop was 683.54% in 2022.
  • IGC Pharma's Change in Inventory stood at -$71000.0 in 2021, then surged by 97.18% to -$2000.0 in 2022, then skyrocketed by 1250.0% to $23000.0 in 2023, then plummeted by 434.78% to -$77000.0 in 2024, then skyrocketed by 92.21% to -$6000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Change in Inventory are -$6000.0 (Q3 2025), -$11000.0 (Q2 2025), and -$73000.0 (Q1 2025).